

BARCELONA
2024

ESMO

congress

Impact of AI Clinical Trial Program on Screening, Matching, and Enrollment of Patients Over a 6 Month Period

Dale Shepard, MD, PhD

Cleveland Clinic
Cleveland, Ohio, United States



Declaration of Interests

Dale Shepard

Aadi, Advisory Board, Personal

Daiichi, Advisory Board, Personal

Deciphera, Advisory Board, Personal

Sanofi, Advisory Board, Personal

Springworks, Invited Speaker, Personal

Aadi, Local PI, Institutional, Financial interest

Cogent, Local PI, Institutional, Financial interest

Compugen, Local PI, Institutional, Financial interest

Conjupro, Local PI, Institutional, Financial interest

Deciphera, Local PI, Institutional, Financial interest

Inhibrx, Local PI, Institutional, Financial interest

Kinnate, Local PI, Institutional, Financial interest

Novartis, Local PI, Institutional, Financial interest

NucMito, Local PI, Institutional, Financial interest

Pfizer, Local PI, Institutional, Financial interest

Prelude, Local PI, Institutional, Financial interest

Seagen, Local PI, Institutional, Financial interest

Tempus AI is Data-Driven Precision Medicine

Improving Patient Care



High-quality testing



Deep research data



Clinical trial matching

6M+

de-identified research records to power scientific discovery to improve patient outcomes

5,000+

oncologists rely on Tempus as their precision medicine partner

2,000+

employees worldwide

160+


biopharma partnerships

50%

of Academic Medical Centers are connected to Tempus across sequencing and data collection

The Tempus AI TIME Program


- **Pre-screening** support via technology and research nurse navigators
- Standardized **trial startup process** eases administrative burden
- **Rapid activation** allows providers to open trials in response to patient need
- Program highlights:
 - Patients identified for trial match - **20,000+**
 - Trial activations completed - **200+**
 - Biopharma partnerships - **160+**
 - Clinical sites active - **110+**



***Testing with Tempus is not required to participate in the TIME program**


Patient Matching with AI Assistance

- 1 NGS & EMR data ingested into TIME platform
- 2 Trial eligibility criteria coded into platform & deploy Natural Language Processing
- 3 Algorithmic matches identified
- 4 Tempus Nurses confirm matches
- 5 High-quality matches sent to clinical site



Tempus AI TIME Program Patient Matching

- Continuously receiving data
- Searches any new patients and re-searches any patients with updated medical data
- Searches as new trials are on-boarded and when trial criteria amendments occur



Tempus AI TIME Program Patients Screened & Consented

Screening and Enrollments	
Nurse Screened Patients	24,533
Interventional Matches	4,443
Interventional Consents	120
Observational Consents	69
Total Consents	189

**Nurses only screen patients for interventional trials*

Nurse Screening

- ~18% of patients passed nursing review and were sent to clinical sites
- Patients were either ready to enroll immediately or monitored on a watchlist
- Tempus LINK is a portal that enables longitudinal following of patients

Tempus AI TIME Program Clinical Trial Activation

Activation Type	Total Activations	Activation Time
Just in Time	44	14.4 days
Prospective	27	38.8 days



Rate Card with pre-negotiated costs



Clinical Trial Agreement for all sites, eliminating repetitive, prolonged negotiations




Standardized ICF & Central IRB to streamline regulatory submissions

Just in Time: Occurs when the patient identified needs to be immediately enrolled on the trial


Prospective: Patient(s) are not yet found but clinical site opens trial with expectations to enroll subjects

Just in TIME Trial Activation

Example Timeline of Patient Enrollment



AI facilitates large-scale clinical trial enrollment overall



BARCELONA
2024

ESMO

congress

Authors:

Dale Shepard (Cleveland Clinic)

Matthias Weiss (ThedaCare)

Bert O'Neil (Community Health Network)

Amol Rao (MemorialCare)

Nihal Abdulla (Cancer and Blood Research Center)

Ahmad Zarzour (The Toledo Clinic)

Kamalesh Kumar Sankhala (NextGen Oncology)

Mark Goldstein (The Center for Cancer and Blood Disorders)

Benjamin Parsons (Gundersen Health System)

Paul La Porte (TOI Clinical Research)

Samantha Mallahan, Chelsea Osterman, Danielle Skelly, Emily Patnaude, Amy Gordon Franzen, Ezra Cohen,

Matthew Cooney (Tempus)

Acknowledgment:

Amrita Iyer (Tempus)

European Society for Medical Oncology (ESMO)

Via Ginevra 4, CH-6900 Lugano

T. +41 (0)91 973 19 00

esmo@esmo.org

esmo.org

